Skip to main content

Table 2 Assessment schedule

From: SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial

Visit date Visit 1 Visit 2 Visit 3 Visit 4
0 day 14 days 3 months 6 months
Demographic data    
Medical/surgical history    
Concomitant diseases  
Concomitant medication/treatment  
Physical examination (vital signs)
Laboratory results (CBC, LFT, PT INR)
ABI
CTA or angiography   
Adverse events  
  1. CBC complete blood cell count, LFT liver function test, PT prothrombin time International Normalized Ratio, ABI ankle–brachial index, CTA computed tomography angiography